Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul-Aug;4(4):445-57.
doi: 10.4161/mabs.20776. Epub 2012 Jul 1.

Molecular engineering of antibodies for therapeutic and diagnostic purposes

Frédéric Ducancel  1 , Bruno H Muller
Affiliations
Review

Molecular engineering of antibodies for therapeutic and diagnostic purposes

Frédéric Ducancel et al. MAbs. 2012 Jul-Aug.

Abstract

During the past ten years, monoclonal antibodies (mAbs) have taken center stage in the field of targeted therapy and diagnosis. This increased interest in mAbs is due to their binding accuracy (affinity and specificity) together with the original molecular and structural rules that govern interactions with their cognate antigen. In addition, the effector properties of antibodies constitute a second major advantage associated with their clinical use. The development of molecular and structural engineering and more recently of in vitro evolution of antibodies has opened up new perspectives in the de novo design of antibodies more adapted to clinical and diagnostic use. Thus, efforts are regularly made by researchers to improve or modulate antibody recognition properties, to adapt their pharmacokinetics, engineer their stability, and control their immunogenicity. This review presents the latest molecular engineering results on mAbs with therapeutic and diagnostic applications.

PubMed Disclaimer

Figures

None
Figure 1. Differential effects of His310 and His435 mutations on FcgammaRIIIA and FcgammaRIIB engagement.
See this image and copyright information in PMC

References

    1. Balint RF, Larrick JW. Antibody engineering by parsimonious mutagenesis. Gene. 1993;137:109–18. doi: 10.1016/0378-1119(93)90258-5. - DOI - PubMed
    1. Sheedy C, MacKenzie CR, Hall JC. Isolation and affinity maturation of hapten-specific antibodies. Biotechnol Adv. 2007;25:333–52. doi: 10.1016/j.biotechadv.2007.02.003. - DOI - PubMed
    1. Labrou NE. Random mutagenesis methods for in vitro directed enzyme evolution. Curr Protein Pept Sci. 2010;11:91–100. doi: 10.2174/138920310790274617. - DOI - PubMed
    1. Lewis L, Lloyd C. Optimisation of antibody affinity by ribosome display using error-prone or site-directed mutagenesis. Methods Mol Biol. 2012;805:139–61. doi: 10.1007/978-1-61779-379-0_9. - DOI - PubMed
    1. Volles MJ, Lansbury PT., Jr. A computer program for the estimation of protein and nucleic acid sequence diversity in random point mutagenesis libraries. Nucleic Acids Res. 2005;33:3667–77. doi: 10.1093/nar/gki669. - DOI - PMC - PubMed

Substances

LinkOut - more resources